Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012Cited by 3k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the FutureKhashayar Esfahani, Wilson H. Miller|Current Oncology|2020Cited by 941
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, John Lenehan et al.|Nature Medicine|2023Cited by 446
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Bo Gao et al.|Journal of Thoracic Oncology|2019Cited by 437
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al.|Journal of Clinical Oncology|2018Cited by 208